Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19083900 | 0.79 | KDM4E (0.40) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL3453126 | 0.70 | PLA2G2C (0.35) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL17722836 | 0.69 | ALDH1A1 (0.37) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL17777044 | 0.69 | ALDH1A1 (0.37) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL17777043 | 0.69 | ALDH1A1 (0.37) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL3452658 | 0.69 | CYP1A2 (0.35) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL3453456 | 0.67 | MAPT (0.32) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL16877065 | 0.67 | MAPT (0.32) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL9522038 | 0.65 | — | — | |
| SCHEMBL17570499 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593149-B2 | Amylin and calcitonin receptor agonist | NOVO NORDISK A/S (DK) | 2017-03-14 | — | — | US | disclosed |
| US-20160272683-A1 | Novel Amylin And Calcitonin Receptor Agonist | NOVO NORDISK A/S (DK) | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272683-A1 | Novel Amylin And Calcitonin Receptor Agonist | SCTR, CALCRL, IAPP | KDM4E 4152/4885MAPT 3535/4885THRB 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.